Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker Metsera.
Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer
Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker Metsera.